Heidelberg Pharma Financials
| HPHA Stock | EUR 2.47 0.01 0.41% |
Heidelberg |
Understanding current and past Heidelberg Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Heidelberg Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Heidelberg Pharma's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Heidelberg Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Heidelberg Pharma AG. Check Heidelberg Pharma's Beneish M Score to see the likelihood of Heidelberg Pharma's management manipulating its earnings.
| Instrument | Germany Stock View All |
| Exchange | Munich Exchange |
| ISIN | DE000A11QVV0 |
| Benchmark | Dow Jones Industrial |
| Currency | EUR - Euro |
You should never invest in Heidelberg Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Heidelberg Stock, because this is throwing your money away. Analyzing the key information contained in Heidelberg Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Heidelberg Pharma Key Financial Ratios
Heidelberg Pharma's financial ratios allow both analysts and investors to convert raw data from Heidelberg Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Heidelberg Pharma over time and compare it to other companies across industries.Heidelberg Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Heidelberg Pharma's current stock value. Our valuation model uses many indicators to compare Heidelberg Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Heidelberg Pharma competition to find correlations between indicators driving Heidelberg Pharma's intrinsic value. More Info.Heidelberg Pharma AG is rated below average in current valuation category among its peers. It is one of the top stocks in price to book category among its peers . The ratio of Current Valuation to Price To Book for Heidelberg Pharma AG is about 7,648,659 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Heidelberg Pharma's earnings, one of the primary drivers of an investment's value.Heidelberg Pharma Systematic Risk
Heidelberg Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Heidelberg Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-six with a total number of output elements of thirty-five. The Beta measures systematic risk based on how returns on Heidelberg Pharma correlated with the market. If Beta is less than 0 Heidelberg Pharma generally moves in the opposite direction as compared to the market. If Heidelberg Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Heidelberg Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Heidelberg Pharma is generally in the same direction as the market. If Beta > 1 Heidelberg Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Heidelberg Pharma January 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Heidelberg Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Heidelberg Pharma AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Heidelberg Pharma AG based on widely used predictive technical indicators. In general, we focus on analyzing Heidelberg Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Heidelberg Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 14.94 | |||
| Value At Risk | (3.49) | |||
| Potential Upside | 1.73 |
Additional Tools for Heidelberg Stock Analysis
When running Heidelberg Pharma's price analysis, check to measure Heidelberg Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heidelberg Pharma is operating at the current time. Most of Heidelberg Pharma's value examination focuses on studying past and present price action to predict the probability of Heidelberg Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heidelberg Pharma's price. Additionally, you may evaluate how the addition of Heidelberg Pharma to your portfolios can decrease your overall portfolio volatility.